# US 2020/0002353 A1 · Heteroaryl estrogen receptor modulators and uses thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2020/0002353 A1
- Document ID: US20200002353A1
- Status: Published application
- Kind: A1
- Application number: 16/565,041
- Filed: 2019-09-09
- Published: 2020-01-02
- Earliest claimed: 2016-06-16
- Assignees: Genentech, Inc.
- Applicants: Genentech, Inc.
- Inventors: Sharada Labadie; Jun Li; Jun Liang; Daniel Fred Ortwine; Xiaojing Wang; Jason Zbieg; Birong Zhang; Nicholas Charles Ray; Simon Goodacre; Jiangpeng Liao
- Web page: https://patentgrep.com/patent/US20200002353A1

## CPC

- C07D 495/04: Ortho-condensed systems
- A61K 31/4355: the heterocyclic ring system containing a five-membered ring having oxygen as a ring hetero atom
- A61K 31/4365: the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
- A61K 31/437: the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
- A61K 31/4375: the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
- A61K 31/4985: Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
- A61K 31/55: having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K 31/695: Silicon compounds
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- C07D 471/04: Ortho-condensed systems
- C07D 471/14: Ortho-condensed systems
- C07D 487/04: Ortho-condensed systems
- C07D 491/048: the oxygen-containing ring being five-membered
- C07F 7/1804: {Compounds having Si-O-C linkages (Si-O-acyl linkages C07F7/1896)}
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07F: ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM (metal-containing porphyrins C07D487/22)

## Abstract

Described herein are heteroaryl compounds with estrogen receptor modulation activity or function having the Formula I, II, and III structures: and stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, and with the substituents and structural features described herein. Also described are pharmaceutical compositions and medicaments that include the Formula I, II, and III compounds, as well as methods of using such estrogen receptor modulators, alone and in combination with other therapeutic agents, for treating diseases or conditions that are mediated or dependent upon estrogen receptors.

## Claims

### Claim 1

A compound of Formula II or III:
or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof, wherein:
A, B, C, and D are independently selected from CR6 and N;
Y1 is CRb or N;
Y2 is —(CH2)—;
Y3 is NRa or C(Rb)2;
where one of Y1 or Y3 is N or NRa;
Ra is independently H, C1-C6 alkyl, C2-C8 alkenyl, propargyl, C3-C6 cycloalkyl, or C3-C6 heterocyclyl, each of which is optionally substituted with one or more groups independently selected from the group consisting of F, Cl, Br, I, CN, OH, OCH3, and SO2CH3;
Rb is independently H, —O(C1-C3 alkyl), C1-C6 alkyl, C2-C8 alkenyl, propargyl, —(C1-C6 alkyldiyl)-(C3-C6 cycloalkyl), C3-C6 cycloalkyl, or C3-C6 heterocyclyl, each of which is optionally substituted with one or more groups independently selected from the group consisting of F, Cl, Br, I, CN, —CH2F, —CHF2, —CF3, —CH2CF3, —CH2CHF2, —CH2CH2F, OH, OCH3, and SO2CH3;
Cy is C6-C20 aryldiyl, C3-C12 carbocyclyldiyl, C2-C20 heterocyclyldiyl, or C1-C20 heteroaryldiyl;
Z1 is CRa or N;
Z2 is O, S or NRa;
Z3 is O, S, NRa, C1-C6 alkyldiyl, C1-C6 fluoroalkyldiyl, O—(C1-C6 alkyldiyl), 0-(C1-C6 fluoroalkyldiyl), C(O), or a bond;
R1, R2, R3, R4, R8, and R9 are independently selected from the group consisting of H, F, Cl, Br, I, —CN, —CH3, —CH2CH3, —CH(CH3)2, —CH2CH(CH3)2, —CH2OH, —CH2OCH3, —CH2CH2OH, —C(CH3)2OH, —CH(OH)CH(CH3)2, —C(CH3)2CH2OH, —CH2CH2SO2CH3, —CH2OP(O)(OH)2, —CH2F, —CHF2, —CH2NH2, —CH2NHSO2CH3, —CH2NHCH3, —CH2N(CH3)2, —CF3, —CH2CF3, —CH2CHF2, —CH(CH3)CN, —C(CH3)2CN, —CH2CN, —CO2H, —COCH3, —CO2CH3, —CO2C(CH3)3, —COCH(OH)CH3, —CONH2, —CONHCH3, —CONHCH2CH3, —CONHCH(CH3)2, —CON(CH3)2, —C(CH3)2CONH2, —NH2, —NHCH3, —N(CH3)2, —NHCOCH3, —N(CH3)COCH3, —NHS(O)2CH3, —N(CH3)C(CH3)2CONH2, —N(CH3)CH2CH2S(O)2CH3, —NO2, ═O, —OH, —OCH3, —OCH2CH3, —OCH2CH2OCH3, —OCH2CH2OH, —OCH2CH2N(CH3)2, —OP(O)(OH)2, —S(O)2N(CH3)2, —SCH3, —S(O)2CH3, —S(O)3H, cyclopropyl, cyclopropylamide, cyclobutyl, oxetanyl, azetidinyl, 1-methylazetidin-3-yl)oxy, N-methyl-N-oxetan-3-ylamino, azetidin-1-ylmethyl, benzyloxyphenyl, pyrrolidin-1-yl, pyrrolidin-1-yl-methanone, piperazin-1-yl, morpholinomethyl, morpholino-methanone, and morpholino; or R3 and R8 form a 4, 5, 6, or 7-membered carbocylic or heterocyclic ring;
R5 is H, C1-C9 alkyl, C3-C9 cycloalkyl, C3-C9 heterocycle, C6-C9 aryl, C6-C9 heteroaryl, —(C1-C6 alkyldiyl)-(C3-C9 cycloalkyl), —(C1-C6 alkyldiyl)-(C3-C9 heterocycle), C(O)Rb, C(O)NRa, SO2Ra, and SO2NRa, optionally substituted with one or more of halogen, CN, ORa, N(Ra)2, C1-C9 alkyl, C3-C9 cycloalkyl, C3-C9 heterocycle, C6-C9 aryl, C6-C9 heteroaryl, C(O)Rb, C(O)NRa, SO2Ra, or SO2NRa; or R3 and R5 form a 4, 5, 6, or 7-membered heterocyclic ring; or Cy and R5 form a 4, 5, 6, or 7-membered heterocyclic ring;
R6 is H, F, Cl, Br, I, —CN, —CH3, —CH2CH3, —CH(CH3)2, —CH2CH(CH3)2, —CH2OH, —CH2OCH3, —CH2CH2OH, —C(CH3)2OH, —CH(OH)CH(CH3)2, —C(CH3)2CH2OH, —CH2CH2SO2CH3, —CH2OP(O)(OH)2, —CH2F, —CHF2, —CH2NH2, —CH2NHSO2CH3, —CH2NHCH3, —CH2N(CH3)2, —CF3, —CH2CF3, —CH2CHF2, —CH2CH2F, —CH(CH3)CN, —C(CH3)2CN, —CH2CN, —CO2H, —COCH3, —CO2CH3, —CO2C(CH3)3, —COCH(OH)CH3, —CONH2, —CONHCH3, —CONHCH2CH3, —CONHCH(CH3)2, —CON(CH3)2, —C(CH3)2CONH2, —NH2, —NHCH3, —N(CH3)2, —NHCOCH3, —N(CH3)COCH3, —NHS(O)2CH3, —N(CH3)C(CH3)2CONH2, —N(CH3)CH2CH2S(O)2CH3, —NO2, ═O, —OH, —OCH3, —OCH2CH3, —OCH2CH2OCH3, —OCH2CH2OH, —OCH2CH2N(CH3)2, —OP(O)(OH)2, —S(O)2N(CH3)2, —SCH3, —S(O)2CH3, —S(O)3H, cyclopropyl, cyclopropylamide, cyclobutyl, oxetanyl, azetidinyl, 1-methylazetidin-3-yl)oxy, N-methyl-N-oxetan-3-ylamino, azetidin-1-ylmethyl, benzyloxyphenyl, pyrrolidin-1-yl, pyrrolidin-1-yl-methanone, piperazin-1-yl, morpholinomethyl, morpholino-methanone, or morpholino;
R7 is H, C1-C6 alkyl, C2-C8 alkenyl, or propargyl; or R7 and Cy form a spiro, 4, 5, 6, or 7-membered carbocyclic or heterocyclic ring; and
n is 1 or 2;
where alkyldiyl, fluoroalkyldiyl, aryldiyl, carbocyclyldiyl, heterocyclyldiyl, and heteroaryldiyl are each optionally substituted with one or more groups independently selected from the group consisting of F, Cl, Br, I, —CN, —CH3, —CH2CH3, —CH(CH3)2, —CH2CH(CH3)2, —CH2OH, —CH2OCH3, —CH2CH2OH, —C(CH3)2OH, —CH(OH)CH(CH3)2, —C(CH3)2CH2OH, —CH2CH2SO2CH3, —CH2OP(O)(OH)2, —CH2F, —CHF2, —CF3, —CH2CF3, —CH2CHF2, —CH2CH2F, —CH(CH3)CN, —C(CH3)2CN, —CH2CN, —CH2NH2, —CH2NHSO2CH3, —CH2NHCH3, —CH2N(CH3)2, —CO2H, —COCH3, —CO2CH3, —CO2C(CH3)3, —COCH(OH)CH3, —CONH2, —CONHCH3, —CON(CH3)2, —C(CH3)2CONH2, —NH2, —NHCH3, —N(CH3)2, —NHCOCH3, —N(CH3)COCH3, —NHS(O)2CH3, —N(CH3)C(CH3)2CONH2, —N(CH3)CH2CH2S(O)2CH3, —NO2, ═O, —OH, —OCH3, —OCH2CH3, —OCH2CH2OCH3, —OCH2CH2OH, —OCH2CH2N(CH3)2, —OP(O)(OH)2, —S(O)2N(CH3)2, —SCH3, —S(O)2CH3, —S(O)3H, cyclopropyl, cyclopropylamide, cyclobutyl, oxetanyl, azetidinyl, 1-methylazetidin-3-yl)oxy, N-methyl-N-oxetan-3-ylamino, azetidin-1-ylmethyl, benzyloxyphenyl, pyrrolidin-1-yl, pyrrolidin-1-yl-methanone, piperazin-1-yl, morpholinomethyl, morpholino-methanone, and morpholino.

### Claim 2 (depends on 1)

The compound of claim 1, wherein A, B, C, and D are each CR6.

### Claim 3 (depends on 1)

The compound of claim 1 having Formula II, wherein Z1 is CRa.

### Claim 4 (depends on 1)

The compound of claim 1 having Formula III, wherein Z2 is O or S.

### Claim 5 (depends on 1)

The compound of claim 1 having Formula III, wherein Z2 is NRa.

### Claim 6 (depends on 1)

The compound of claim 1, wherein Cy is phenyldiyl substituted with one or more halo groups.

### Claim 7 (depends on 1)

The compound of claim 1, wherein Z3 is O or NRa.

### Claim 8 (depends on 7)

The compound of claim 7, wherein Z3 is NH.

### Claim 9 (depends on 1)

The compound of claim 1, wherein Z3 is O—(C1-C6 alkyldiyl), Y1 is N, and Y3 is C(Rb)2.

### Claim 10 (depends on 9)

The compound of claim 9, wherein Y3 is CH(CH2F).

### Claim 11 (depends on 1)

The compound of claim 1, wherein Y1 is CRb and Y3 is NRa.

### Claim 12 (depends on 11)

The compound of claim 11, wherein Y3 is NCH2CH2CH2F.

### Claim 13 (depends on 1)

The compound of claim 1, wherein R5 is C1-C9 alkyl substituted with one or more F.

### Claim 14 (depends on 1)

The compound of claim 1 wherein the compound is a compound of formula (II) having the structure:
or a pharmaceutically acceptable salt thereof.

### Claim 15 (depends on 1)

The compound of claim 1 wherein the compound is a compound of formula III having the structure:
or a pharmaceutically acceptable salt thereof.

### Claim 16 (depends on 1)

A pharmaceutical composition comprising a compound of claim 1 and at least one pharmaceutically acceptable excipient.

### Claim 17 (depends on 1)

A method of treating breast cancer, lung cancer, ovarian cancer, endometrial cancer, prostate cancer, or uterine cancer in a patient having such cancer, the method comprising administering a therapeutically effective amount of a compound of claim 1.

### Claim 18 (depends on 17)

The method of claim 17, further comprising administering an additional therapeutic agent selected from the group consisting of an anti-inflammatory agent, an immunomodulatory agent, a chemotherapeutic agent, an apoptosis-enhancer, a neurotropic factor, an agent for treating cardiovascular disease, an agent for treating liver disease, an anti-viral agent, an agent for treating blood disorders, an agent for treating diabetes, and an agent for treating immunodeficiency disorders.

### Claim 19 (depends on 18)

The method of claim 18, wherein the additional therapeutic agent is selected from the group consisting of paclitaxel, anastrozole, exemestane, cyclophosphamide, epirubicin, fulvestrant, letrozole, palbociclib, gemcitabine, trastuzumab (HERCEPTIN®, Genentech), trastuzumab emtansine (KADCYLA®, Genentech), pegfilgrastim, filgrastim, tamoxifen, docetaxel, toremifene, vinorelbine, capecitabine, and ixabepilone.

### Claim 20 (depends on 18)

The method of claim 18, wherein the additional therapeutic agent is a CDK 4/6 inhibitor comprising palbociclib (PD-0332991), ribociclib (LEE011), or abemaciclib (LY283519).

### Claim 21 (depends on 18)

The method of claim 18, wherein the additional therapeutic agent is administered a phosphoinositide 3-kinase (PI3K)/mTOR pathway inhibitor selected from the group consisting of everolimus, temsirolimus, BEZ235 (dactolisib), BYL719 (alpelisib), GDC0032 (taselisib), BKM120 (buparlisib), BGT226, GDC0068 (ipatasertib), GDC-0980 (apitolisib), GDC0941 (pictilisib), INK128 (MLN0128), INK1117, OSI-027, CC-223, AZD8055, SAR245408, SAR245409, PF04691502, WYE125132, GSK2126458, GSK-2636771, BAY806946, PF-05212384, SF1126, PX866, AMG319, ZSTK474, Cal101 (idelalisib), PWT33597, CU-906, AZD-2014 and CUDC-907.
